NCT01330979

24-hour Efficacy of AR-12286

A Phase 2 Open Label Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Open-angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension

Conditions

• Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	AR-12286 0.5% Ophthalmic Solution	Ophthalmic Solution

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2011-04-07
• Last updated: 2014-04-21

Locations

1 site across 1 country: United States